| First Author | Naert G | Year | 2012 |
| Journal | Mol Med | Volume | 18 |
| Pages | 297-313 | PubMed ID | 22160221 |
| Mgi Jnum | J:310366 | Mgi Id | MGI:6762921 |
| Doi | 10.2119/molmed.2011.00306 | Citation | Naert G, et al. (2012) Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. Mol Med 18:297-313 |
| abstractText | Monocytes emigrate from bone marrow, can infiltrate into brain, differentiate into microglia and clear amyloid beta (Abeta) from the brain of mouse models of Alzheimer's disease (AD). Here we show that these mechanisms specifically require CC-chemokine receptor 2 (CCR2) expression in bone marrow cells (BMCs). Disease progression was exacerbated in APP(Swe)/PS1 mice (transgenic mice expressing a chimeric amyloid precursor protein [APPSwe] and human presenilin 1 [PS1]) harboring CCR2-deficient BMCs. Indeed, transplantation of CCR2-deficient BMCs enhanced the mnesic deficit and increased the amount of soluble Abeta and expression of transforming growth factor (TGF)-beta1 and TGF-beta receptors. By contrast, transplantation of wild-type bone marrow stem cells restored memory capacities and diminished soluble Abeta accumulation in APP(Swe)/PS1 and APP(Swe)/PS1/CCR2(-)/(-) mice. Finally, gene therapy using a lentivirus-expressing CCR2 transgene in BMCs prevented cognitive decline in this mouse model of AD. Injection of CCR2 lentiviruses restored CCR2 expression and functions in monocytes. The presence of these cells in the brain of non-irradiated APP(Swe)/PS1/CCR2(-)/(-) mice supports the concept that they can be used as gene vehicles for AD. Decreased CCR2 expression in bone marrow-derived microglia may therefore play a major role in the etiology of this neurodegenerative disease. |
